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ABSTRACT The uterine expression of leukemia inhibi-
tory factor (LIF) is essential for embryo implantation in the
mouse. Here, we describe the expression of LIF, related
members of this group of cytokines, oncostatin M and ciliary
neurotrophic factor, and the LIF receptor j3 and glycoprotein
gpl30 in normal human tissues and in the endometrium of
fertile women. Our results show that LIF is the only one of
these factors expressed at detectable levels in the endome-
trium ofwomen of proven fertility. LIF expression is restricted
to the endometrial glands during the secretory/postovulatory
phase but is not present in the endometrium during the
proliferative/preovulatory phase. The LIF receptor j3 is ex-
pressed during the proliferative and secretory phases of the
cycle and is restricted to the luminal epithelium. The associ-
ated signal-transducing component of the LIF receptor,
gpl30, is also expressed in both the luminal and glandular
epithelium throughout the cycle. These results suggest that
uterine expression of LIF in humans, like mice, may have a
role in regulating embryo implantation, possibly through an
autocrine/paracrine interaction between LIF and its receptor
at the luminal epithelium.
A critical stage in early mammalian embryonic development is
implantation, when the blastocyst becomes closely associated
with the maternal endometrial tissues. Although the regulation
of implantation is not clearly understood, it is evident that the
steroid hormones, including estrogen and progesterone, in-
duce essential proliferative and differentiative changes in the
endometrium that lead to a temporary state of uterine recep-
tivity and permit embryo implantation (1). Recent studies have
revealed that many cytokines and growth factors play an
essential role in preimplantation development (2-4). These
cytokines are expressed in the female reproductive tract and
may be the effectors of the steroid hormones. Among these
factors, epidermal growth factor (EGF) or an EGF-like mol-
ecule has been implicated in regulating endometrial cell
proliferation (5) and in some strains of mice embryonic
expression of the EGF receptor is essential for development of
the peri-implantation embryo (6). Colony-stimulating factor-1
(CSF-1) has an important, although undefined role in a
successful pregnancy (7). It has also been suggested that
interleukin-1 (IL-1) and its receptor may be required in
mediating blastocyst implantation (8). Finally, the expression
of leukemia inhibitory factor (LIF) in mice is absolutely
essential for implantation, although its precise role is not fully
understood (9).
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In the mouse, the principal sites of LIF expression are the
endometrial glands of the uterus. Expression in the uterus is
temporally restricted, with peak levels occurring at ovulation
and just prior to the onset of blastocyst implantation. LIF
expression is under maternal control and is not dependent
upon the presence of embryos in the uterus (10, 11). Direct
evidence that LIF is an absolute requirement for implantation
was obtained by the derivation of mice deficient in a functional
LIF gene. LIF-deficient male mice are fertile, and while the
females ovulate and their embryos develop to the blastocyst
stage, the embryos fail to implant. Implantation and normal
development of these embryos can occur when they are
transferred from the LIF-deficient mothers to wild-type pseu-
do-pregnant recipients or when an exogenous supply of LIF is
provided to the LIF-deficient females (9).
LIF is a member of a family of ligands that include inter-
leukin 6 (IL-6), oncostatin M (OSM), ciliary neurotrophic
factor (CNTF), and the recently identified cardiotrophin-1 (12,
13). These factors exhibit functional redundancy, since they
have similar effects in a variety of biological systems, including
the inhibition of embryonic stem cell differentiation in vitro
and the induction of acute-phase protein synthesis in hepato-
cytes (14, 15). They also have structural similarities and all
interact with the shared signal-transducing receptor compo-
nent, glycoprotein gpl30. With the exception of IL-6, they can
interact with the LIF receptor f3 (LIFr/3), the principal trans-
membrane protein that binds LIF (16). The functional redun-
dancies and shared activities of the LIF family of cytokines
suggest that LIF, as well as CNTF, OSM, or IL-6 might also be
expressed in human endometrium and that any one of these
factors could serve to regulate preimplantation development
and embryo implantation.
Here we describe the expression of the LIF, CNTF, OSM
and the LIF receptor (LIFrI3 and gpl30) in normal human
tissues, with particular emphasis on the expression in the
uterus during different phases of the menstrual cycle. We
demonstrate that LIF expression is restricted predominantly to
the glandular and luminal epithelium, with maximal levels of
synthesis occurring during the secretory/postovulatory phase
of the menstrual cycle (starting around days 18-21), the time
at which implantation is thought to commence. LIF continues
to be expressed in the endometrium of first and second
trimester pregnancy. Both LIFr/3 and gpl30 are expressed
throughout the cycle, with the LIFrj3 being restricted to the
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luminal epithelia and gpl30 being expressed in both the
glandular and luminal epithelium. These results, together with
the known requirement of LIF in the mouse, suggest that LIF
may have a similar effect in regulating implantation in human
reproduction, possibly through an autocrine/paracrine inter-
action with the LIFrf3, that acts on the luminal epithelium.
MATERIALS AND METHODS
Isolation of Tissue Samples. Endometrial samples from
normal women of proven fertility were obtained by biopsy at
tubal ligation. All samples were taken following the informed
consent of the patients. All patients were cycling normally, and
none had received hormone therapy. Endometrium was col-
lected according to the last menstrual period and confirmed
according to the methods of Noyes et al. (17). Days in the
menstrual cycle were expressed in all figures where the first day
of menses is day 1, ovulation is day 14, and the cycle length is
28 days. Samples of endometrium were obtained during preg-
nancy from the three trimesters and dated as described (17).
All samples were transported on ice to the laboratory where
they were snap-frozen in liquid nitrogen and stored at -80°C
or were immediately fixed in phosphate-buffered 3.5% para-
formaldehyde. Specimens of pregnant endometrium from four
separate patients were examined by immunohistochemistry,
and 20 highly purified mRNA preparations of pregnant en-
dometrium were examined by RNA blot hybridization (North-
ern) analysis. Utilization of endometrial tissue had been
approved by the institutional review board.
Immunoblotting (Western Blotting). The anti-human LIF
antibody was raised against a peptide composed of amino acids
162-179 of the mature human LIF protein. The peptide was
conjugated to keyhole limpet hemocyanin, emulsified in
Freund's complete adjuvant, and injected subcutaneously into
a rabbit. After 3 monthly injections, serum was tested by
Western analysis of human recombinant LIF protein and
endometrial protein extracts. Frozen endometrial tissues were
pulverized and then homogenized in buffer containing 0.1%
SDS, 1% Triton X-100, 1% sodium deoxycholate, 0.15 M
NaCl, 0.01 M Tris-HCl (pH 7.4), 1 mM EDTA, 0.25 mM
phenylmethylsulfonyl fluoride, 2 ,ug of aprotinin per ml, and 1
jig of pepstatin per ml. Lysates (20 ,Ig per lane) were resolved
by using Bio-Rad Mini-Gel and transfer apparatus. Mem-
branes were blocked in 2.5% horse sera and 0.5% bovine
serum albumin. Anti-human LIF antisera and preimmune sera
from the same rabbit were used at 1:1000 dilution, and
horseradish peroxidase-linked donkey anti-rabbit IgG anti-
body (Amersham) was used at 1:5000 dilution. Visualization of
signal was by enhanced chemiluminescence (Amersham).
Probes and Labeling. Plasmids containing either human
gpl30 or human OSM were provided by David Gearing
(SyStemix, Palo Alto, CA). The human LIF receptor cDNA
fragment was obtained from Nancy Ip (Regeneron Pharma-
ceuticals, Tarrytown, NY). The human CNTF probe was
obtained from David Hirsch (Columbia University). The
probe for RPL19 was generated from primers previously
described (18). The human actin probe was obtained from
Clontech. The human LIF cDNA was purchased from British
Biotechnology (Oxford). The probe for CNTF receptor
(CNTFr) was generated from the previously published se-
quence. Probes were purified and labeled to high specific
activity by random priming with 6000 Ci/mmol of dCTP
(Amersham; 1 Ci = 37 GBq). Labeled fragments were purified
through Pharmacia NICK columns.
RNA Isolation and Northern Analysis. Frozen samples of
staged human endometrium were homogenized and extracted
in 15 ml of RNAzol B (Biotecx Laboratories, Houston).
Twenty micrograms of total RNA was electrophoresed, trans-
ferred to Genescreen Plus-charged nylon membranes (Du-
Pont/NEN) and hybridized according to the manufacturer's
instructions. Uterine mRNA and multiple-tissue Northern
blots were purchased from Clontech and hybridized according
to the manufacturer's instructions. Data concerning the stage
in the cycle of the uterine mRNA on the Clontech filters was
not available.
In Situ Hybridization and Immunohistochemistry. Endo-
metrial tissue was removed from patients and placed directly
in OCT (embedding compound) tissue tek (Baxter Scientific
Products, McGaw Park, IL) or snap frozen prior to OCT, and
sectioned at 10-,um thickness. Synthesis of digoxigenin-labeled
RNA probes and in situ hybridization was performed as described
(19). Immunohistochemical localization of LIF antigen was per-
formed on cryostat sections of endometrium taken from patients
staged throughout the menstrual cycle and performed as de-
scribed (20, 21) by using the Vectastain Elite ABC kit (Vector
Laboratories) (19). Endometria from pregnancies were fixed in
3.5% paraformaldehyde in phosphate-buffered saline, sectioned
at 5 ,um, and stained as described (22).
RESULTS
Tissue-Specific Expression of Human LIF, LIF-Related
Cytokines, and Receptors. Since the expression of the LIF-
related cytokines in humans has not yet been documented,
expression of LIF and LIF-related cytokines was examined in
16 normal adult human tissues by Northern analysis (Fig. 1A).
LIF transcripts (4.4 kb) were detected in all tissues examined
except the brain, testis, skeletal muscle, and peripheral blood
leukocytes (PBL). A second larger 5.0-kb LIF transcript was
also detected in the small intestine and colon. In contrast, a
2.2-kb OSM transcript was strongly expressed only in PBL and
a 2.4-kb CNTF transcript was detectable at low levels in the testis.
The tissue-specific expression of receptor subunit transcripts
for the LIF family, LIFr,3, CNTFr, and the signal transducer,
gpl30, was also examined (Fig. 1A). The LIFr,3 message is
expressed in most tissues as 11.0, 8.0 and 6.5 kb mRNAs except
that testis produced an additional 4.4-kb transcript and ex-
pression of LIFr/3 mRNA in PBL was very low. The CNTFr
was detected only in the brain and skeletal muscle as a 2.2-kb
transcript. The receptor component gpl30 was expressed in all
tissues as an 8.5 kb mRNA species (Fig. 1A).
Expression of Human LIF in Normal Endometrium. Ex-
pression of LIF, CNTF, and OSM transcripts was examined in
endometria from women of proven fertility at different days
throughout the menstrual cycle and in early pregnancy. Only
LIF transcripts were detected, whereas CNTF and OSM
transcripts were absent in the same endometrial samples (Fig.
1B). LIF transcripts were apparent by the end of the early-
secretory phase on day 18 and persisted throughout mid- and
late-secretory phases. LIF expression in the endometrium
continued into pregnancy with low levels detected during the
first trimester (Fig. 1B). In the mid-to-late second and third
trimester, LIF transcripts were also detected at lower levels
(total of eight samples analyzed, and data not shown). Expres-
sion of IL-6 in human endometrial epithelium has been
previously described and was not reexamined (3).
Localization of LIF mRNA. Specific cell types expressing
LIF transcripts were identified by in situ hybridization of
proliferative and secretory phase endometrium (Fig. 2). Post-
ovulatory endometrial samples (n = 6) obtained from women
of proven fertility express LIF in the glandular and luminal
epithelium but not in the stroma (Fig. 2 C and D). Proliferative
samples, also from women of proven fertility (n = 2) show an
absence of LIF expression in the glandular and luminal
epithelia as well as the stroma (Fig. 2 A and B).
LIF Protein Expression in Endometrium. Western blot
analysis of endometrial protein extracts were used to test the
specificity of the anti-human LIF antisera (Fig. 1D). Two
immunoreactive species of 45 and 40 kDa were resolved from
endometrial lysates of secretory-phase samples (Fig. 1D, lane
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FIG. 1. Cytokine expression in human tissues and endometrium. (A) Northern analysis of human multiple tissue blots hybridized to LIF, CNTF,
OSM, LIFrj3, gpl30, and CNTFr. Actin and RPL19 probes were used to control for loading. (B) Northern analysis of RNA expression in human
endometrium for LIF and gpl30. Endometrial biopsy samples are presented as either in the proliferative or secretory phase and are designated
by a cycle day, where the first day of menses is day 1, ovulation is day 14, and the menstrual cycle is 28 days. Endometrial RNA made from first
trimester pregnancy is also shown. An RNA sample from a patient diagnosed as anovulatory is designated by an asterisk. The actin message increases
during mid- and late-secretory phases and is not an adequate quantitative control for loading, as reported (23). However, the RPL19 transcript,
which is nonresponsive to estrogen, can be used as an internal control for endometrial RNA loading (18). (C) Northern blot analysis of LIFrf3
expression in 2 'jg of purified mRNA from pooled human uteri. (D) Western blot analysis of human endometrial samples using anti-LIF antibody.
Endometrial protein extracts from proliferative-phase day 6 (lane A) and secretory-phase day 18 (lane B). The anti-human LIF antiserum recognizes
two protein bands at 45 and 40 kDa in secretory-phase samples but does not recognize these proteins in proliferative samples. Preimmune serum
does not recognize these bands (lane C). In competition studies, antibody binding to the 45- and 40-kDa protein bands is competitively blocked
with 50 tg of LIF peptide per ml. A second commercially available LIF antibody (R & D Systems) also recognizes these two bands (data not shown).
B). These species were absent from endometrium of the
proliferative phase (Fig. 1D, lane A). Similar results were also
obtained with a commercially available antiserum (R & D
Systems; data not shown). Preimmune sera did not detect the
40- and 45-kDa protein species (Fig. 1D, lane C). The speci-
ficity of the anti-human LIF antibody was tested by competi-
tion assay using the LIF peptide, which resulted in disappear-
ance of these two bands (data not shown).
Immunohistochemical staining with the LIF antibody de-
tected LIF protein in the glandular and luminal epithelium,
consistent with expression of LIF mRNA in the endometrium
during the secretory phase of the menstrual cycle (Fig. 3).
Immunoreactive LIF was observed in sections of endometrium
from the mid- and late-secretory phases (Fig. 3B) but not in
sections from the proliferative phase (Fig. 3A).
We also determined by Northern analysis that LIF was
expressed in postimplantation endometrium and that the level
of expression appeared higher during earlier stages of preg-
nancy (data not shown). An immunohistochemical analysis of
the postimplantation endometrium showed LIF staining in the
luminal epithelium is more intense in the first trimester (Fig.
3C) than in the second trimester (data not shown). In addition,
at 5 weeks of gestation, strongly positive cells are detected in
the decidualizing stroma at locations immediately adjacent to
the luminal epithelium but more distal to the glands (Fig. 3 C
and D). By 16 weeks of gestation, the staining in the decidua
is largely absent (data not shown). Immunoreactivity could be
competively blocked with LIF peptide (Fig. 3E) and was not
detected with preimmune serum (Fig. 3F).
LIF Receptor Expression During the Normal Menstrual
Cycle. Expression of LIFr/3 and gpl30 was examined in normal
endometrial RNA samples (Fig. 1 B and C). gpl30 transcripts
were detected in all samples with expression increasing in mid-
and late-secretory phases (Fig. 1B). LIFr3 transcripts could
not be detected by Northern analysis of total RNA, possibly
because of low levels of expression or partial degradation of
high molecular weight RNA. However, an 11.0-kb LIFr,B
transcript was the predominant message detected in purified
mRNA from pooled samples of human uteri (Fig. 1C). CNTFr
transcripts were not detected in human endometrium during
any day of the cycle (data not shown), and the OSM receptor
has not yet been identified.
Localization of LIF Receptor mRNA. Since the LIFr,3
mRNA could not be detected by Northern analysis of total
RNA, the presence of the mRNA was examined in the luminal
epithelium by in situ analysis with an antisense LIFrf3 mRNA
probe (Fig. 2 G and H) from both secretory (n = 3)- and
proliferative (n = 2)-phase endometria. LIFr,3 transcripts were
detected in the luminal epithelium but not in the stroma or
glandular epithelium. gpl30 was expressed throughout the
cycle and was restricted to both the glandular and luminal
epithelia, with expression peaking during the secretory phase
of the cycle (Fig. 2 E and F). No gpl30 was detected in the
stromal tissue in any of the samples analyzed.
DISCUSSION
These studies show that the tissue specificity of LIF expression
in most human tissues is essentially identical to those in the
mouse (10, 24). Both OSM and CNTF expression is more
restricted than LIF, with OSM only being detected in PBL.
CNTF was expressed at low levels in the testis, similar to results
seen in rats (25). Although the cytokines can display functional
redundancy in vitro, it appears that their expression is strictly
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FIG. 2. In situ analysis of LIF and LIFrj3 RNA expression in endometrium. (A) Proliferative-stage biopsy on day 12 of the cycle, digoxigenin
(dig)-LIF sense probe. (B) Serial section of same biopsy asA, with dig-LIF antisense probe revealing no detectable expression of LIF. (C) Secretory
stage biopsy on day 22 with dig-LIF sense probe. (D) Serial section of same biopsy as C with dig-LIF antisense probe. The LIF antisense probe
binds specifically to luminal and glandular epithelia in secretory-phase samples but not to proliferative-phase samples. (E) Signal-transducing
portion, gpl30 sense probe, hybridized to late-secretory phase/menses endometrium. (F) Serial section ofE hybridized to dig-gp130 antisense probe.
(G) dig-LIFr/3 sense probe hybridized to day 22 secretory-phase biopsy. (H) Serial section of same biopsy as E. dig-LIFr3 antisense probe hybridizes
to the luminal epithelium.
regulated in vivo and that in any particular tissue the expression
of more than one LIF-related cytokine normally does not occur.
Our analysis revealed that human LIF expression occurs
predominantly in the uterine endometrium; that the onset of
transcription starts around days 18-21 of the cycle, in agree-
ment with previous observations (26, 27); and that uterine
expression persists throughout the first trimester of pregnancy.
A combined mRNA in situ and immunohistochemical analysis
indicated that LIF expression is restricted to the glandular and
luminal epithelium during the secretory/postovulatory phase
of the cycle. Western analysis on the uterine samples revealed
that two forms of the LIF protein are expressed. The molecular
basis for producing these two forms has not yet been estab-
lished and may either correspond to alternatively spliced forms
or to differences in glycosylation that are found in the mouse
(28, 29).
The patterns of LIF expression in the human and mouse
endometrium differ slightly. In the mouse, two peaks of
expression are detected, with the first occurring at ovulation
and the second around the onset of implantation. Both bursts
of expression last -24 hr (10, 11). The cellular localization of
the ovulatory peak has not yet been determined, whereas the
peak at implantation is restricted to the epithelium of the
endometrial glands. In the human, we found no evidence to
indicate a peak of expression occurring around the time of
ovulation. Human LIF expression occurs in the luminal epi-
thelium, as well as the glands, whereas, murine LIF expression
is restricted to the glands. In both species, if pregnancy occurs,
LIF expression in the endometrium persists in the luminal and
glandular epithelium. During pregnancy additional and as yet
unidentified strongly LIF-expressing cells are found in the
Proc. Natl. Acad. Sci. USA 93 (1996)
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FIG. 3. LIF expression in human endometrium during the proliferative and secretory phase of the menstrual cycle and in pregnant endometrium.
Immunohistochemical analysis of endometrial sections using rabbit anti-LIF antibody (A). LIF staining of endometrium late-proliferative to
early-secretory phase. (B) LIF staining of glandular epithelium day 22 secretory phase. (C and D) LIF staining of pregnant endometrium, 5 weeks
gestation. Note staining of both the glandular and luminal epithelium. (E) LIF peptide inhibition of LIF staining of decidualized endometrium.
(F) Preimmune sera staining. Other staining cells, probably macrophages, are found scattered in the stroma (C and D from a total of six individual
samples analyzed). The identity of the epithelial cells was confirmed by staining adjacent sections with rabbit anti-cytokeratin antibody (data not shown).
decidualizing stroma at locations immediately adjacent to the
luminal epithelium. Likewise, low levels of LIF expression
occur in murine endometrium and decidua throughout preg-
nancy (10). We do not yet know if the continued expression of
LIF is essential for the maintenance of pregnancy.
The significance of any differences in LIF expression be-
tween the mouse and human is not yet apparent. In the mouse,
it is unlikely that there is an absolute requirement for the
ovulatory burst of LIF expression, since mice deficient in LIF
can ovulate and form viable blastocysts. Implantation of these
embryos can be induced in the LIF-deficient mice if an
exogenous source of LIF is provided on day 3 of gestation,
indicating that LIF expression at ovulation is not required for
preimplantation development or embryo implantation (9).
Although there is an absolute requirement for LIF at
implantation in the mouse, neither CNTF nor IL-6 are re-
quired, as mice deficient in either of these factors show no
impairment in their development or reproduction (30-32).
Similarly, humans deficient in CNTF have been identified with
no overt phenotypic effect (33). As a preliminary attempt to
determine whether defective LIF expression might have a role
in human infertility, we analyzed expression in samples taken
from 49 patients with some form of infertility. All but two
patients expressed detectable LIF transcripts during their
secretory phase, indicating that alterations in LIF expression
are unlikely to be a major contributory factor to infertility in
females. The cause for the apparent lack of LIF expression in
the two remaining patients remains unclear, although it is still
under investigation.
In LIF-deficient mice, decidualization does not occur after
the appropriate hormonal priming followed by oil injection or
traumatization of the uterus, revealing that LIF is normally
required to place the endometrium in a receptive state where
embryos can implant and the stroma decidualize (unpublished
observations). Our analysis of the cellular pattern of expres-
sion of LIF and the LIFr,3 in humans has provided some
important indications as to how LIF may regulate implanta-
tion. The results reveal that expression of LIFrj3 is restricted
to the luminal epithelium, with expression of gpl30 occurring
in both the luminal and glandular epithelium. Neither of these
two receptor components appears to be expressed in the
stromal cells. A similar restriction in expression of these two
factors has also been noted in the mouse (unpublished obser-
vations). The patterns of expression of LIF and its receptor
strongly suggest that LIF does not directly affect the stroma but
acts on the luminal epithelium, possibly through an autocrine/
paracrine route. In response to elevated levels of estrogen (10),
LIF may act to initially "sensitize" the luminal epithelium and
this, together with an additional stimulus such as that associ-
ated with either blastocyst attachment or injection of oil into
the uterine lumen, induces a luminal epithelium-stromal in-
teraction, resulting in decidualization of the stroma. This is
Muedical Sciences: Cullinan et al.
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consistent with the observations that initiating decidualization
in rodents requires a stimulus to act through the luminal
epithelium (34) and that in rats, decidua formation cannot be
induced in utero in which the luminal epithelium has been
removed (35). Whether LIF also induces changes in the
luminal epithelium to permit blastocyst attachment and induce
other factors, such as EGF-related factors (6), required by the
implanting embryo remains to be determined.
In summary, these observations provide further evidence for
the crucial role cytokines play in regulating fetal-maternal
interactions during pregnancy. The data strongly support a role
for the endometrial synthesis of LIF in mediating uterine
receptivity for blastocyst implantation by binding to LIF
receptors on the luminal epithelium.
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